Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
25.3M
-
Shares change
-
+2.02M
-
Total reported value, excl. options
-
$49.3M
-
Value change
-
+$4.79M
-
Number of buys
-
23
-
Number of sells
-
-18
-
Price
-
$1.95
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q1 2017
62 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q1 2017.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.3M shares
of 123M outstanding shares and own 20.54% of the company stock.
Largest 10 shareholders include Broadfin Capital, LLC (8.2M shares), BAKER BROS. ADVISORS LP (5.1M shares), venBio Select Advisor LLC (3.8M shares), VANGUARD GROUP INC (3.01M shares), Point72 Asset Management, L.P. (877K shares), Candriam Luxembourg S.C.A. (600K shares), BlackRock Inc. (553K shares), GEODE CAPITAL MANAGEMENT, LLC (463K shares), RENAISSANCE TECHNOLOGIES LLC (382K shares), and Knott David M (284K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.